Sensitization to isothiazolinones in the Spanish Contact Dermatitis Registry (REIDAC): 2019–2021 epidemiological situation

Background: Current frequency and risk factors for sensitization to methylisothiazolinone (MI), methylchloroisothiazolinone/methylisothiazolinone (MCI/MI), benzisothiazolinone (BIT) and octylisothiazolinone (OIT) in Spain are not well known. Objectives: To study the frequency of sensitization, risk factors and simultaneous sensitization between the four isothiazolinones. Materials and Methods: We analysed all 2019-2021 consecutive patients patch-tested with MI (0.2% aq.), MCI/MI (0.02% aq.), BIT (0.1% pet.) and OIT (0.1% pet) within the Spanish Contact Dermatitis Registry (REIDAC). Results: A total of 2511 patients were analysed. Frequencies of sensitization were: any isothiazolinone 15.7%, MI 6.8%, MCI/MI 4.8%, BIT 3.5% and OIT 0.5%. MI and MCI/MI sensitization was associated with being occupationally active, hand dermatitis, detergents and age over 40. BIT sensitization was associated with leg dermatitis and age over 40. About one in nine MI-positive patients were positive to BIT, whereas one in five BIT-positive patients were positive to MI. Conclusions: Sensitization to MI, MCI/MI and BIT is still common in Spain, while sensitization to OIT is rare. Currently, sensitization to MI and MCI/MI seems to be occupationally related. Although its origin is unknown, sensitization to BIT is more frequent in patients aged over 40 years. Simultaneous sensitization between MI and BIT is uncommon.The Spanish Registry of Contact Dermatitis (REIDAC) is promoted by the Fundación Piel Sana (Academia Española de Dermatología y Venereología), which has received financial support from the Spanish Medicines and Health Products Agency (Agencia Española de Medicamentos y Productos Sanitarios. https://www.boe.es/boe/dias/2022/04/11/pdfs/BOE-A-2022-5975.pdf) and Sanofi. The funders were not involved in the design and conduct of the study, collection, management, analysis and interpretation of data, preparation, review, approval of the manuscript, or decision to submit the manuscript for publication

Tumores vasculares como marcadores sindrómicos

Los hemangiomas pueden ser marcadores o signos guía de síndromes graves. Aunque menos conocidos que los relacionados con malformaciones vasculares, existen algunos síndromes de importante valor diagnóstico que se asocian a hemangiomas. El reconocimiento precoz de los hemangiomas de alto riesgo, junto a una rápida actuación, puede ayudar a minimizar su morbilidad futura. Los hemangiomas en neonatos requieren un seguimiento especial, debido a que su patrón de crecimiento puede ser imprevisible a una edad tan temprana. Diversas presentaciones clínicas son relevantes por su riesgo de asociación sindrómica: los hemangiomas cervicofaciales, especialmente los de gran tamaño, pueden ser marcadores de trastornos dismórficos graves como el síndrome PHACE(S). Los que se distribuyen en el área de la barba se asocian en ocasiones a hemangiomas de la vía aérea. Los hemangiomas lumbosacros suelen ocultar un disrafismo espinal o malformaciones anorrectales y urogenitales. Los hemangiomas cutáneos múltiples pueden ser signo de una hemangiomatosis visceral, con más frecuencia hepática, que se complique con insuficiencia cardíaca o enfermedad tiroidea. Por último, existen dos neoplasias vasculares de crecimiento rápido e invasor, distintas del hemangioma del lactante (el hemangioendotelioma kaposiforme y el angioblastoma o hemangioma ¿en penachos¿), que son marcadores del síndrome de Kasabach-Merritt. Palabras clave. Hemangioma del lactante. Tumor vascular. Hemangiomatosis. Marcador clínico. Síndrome PHACE(S)

The European baseline series: Criteria for allergen inclusion (with reference to formaldehyde releasers)

Data de publicació electrònica: 21-03-2021Existing criteria for inclusion in the European baseline series are summarized. Additional criteria are developed to aid decision making where the current criteria do not yield an unequivocal result. These include a consideration of whether an allergen (hapten) is better placed in a special series and the frequency with which an allergen cross-reacts with existing markers in the baseline series